The plasmacytoid carcinoma of the bladder - rare variant of aggressive urothelial carcinoma

B. Keck, R. Stoehr, S. Wach, A. Rogler, F. Hofstaedter, J. Lehmann, R. Montironi, M. Sibonye, H. M. Fritsche, A. Lopez-Beltran, Jonathan Ira Epstein, B. Wullich, A. Hartmann

Research output: Contribution to journalArticle

Abstract

The WHO classification of 2004 defines new histological and molecular variants of urothelial carcinoma. However there are limited data available on the clinico-pathological characteristics or prognosis of these variants. We present histopathological, molecular and clinical data of 32 plasmacytoid carcinomas of the bladder (PUC) showing that PUC is a high-grade tumor with molecular features of aggressive urothelial carcinoma, usually diagnosed in advanced pathological stage (64% pT3, 23% pT4) showing metastases in 60 % of the patients. Average survival of our cohort of PUC treated with radical cystectomy and adjuvant chemotherapy was lower than what is typically seen for comparable conventional urothelial carcinomas. 87% of the PUCs showed a negative or strongly reduced membranous staining of E-cadherin. Beta-catenin staining was negative in 22.5% and 16.7% of the remaining tumors showed nuclear accumulation. Aberrant CK20 expression (negative or > 10% of cells stained) and negative CK7 staining was found in 100% and 22.6%, respectively. 97% revealed positive staining for PAN-CK. CD138 was positive in 78 %, whereas MUM-1 expression was negative in all cases. Multi-target fluorescence in situ hybridization showed all PUCs to be highly aneuploid and polysomic. Deletions on chromosome 9p21 seem to play an important role in this variant. FGFR3 and PIK3CA mutation analyses yielded no mutations in any of the PUCs analyzed. TP53 mutation analysis showed mutations in 29%. In summary, PUC is a aggressive variant of bladder cancer with molecular features of advanced bladder cancer and evidence of WNT pathway activation in some of the cases.

Original languageEnglish (US)
Pages (from-to)770
Number of pages1
JournalInternational Braz J Urol
Volume36
Issue number6
DOIs
StatePublished - Dec 2010
Externally publishedYes

Fingerprint

Urinary Bladder
Carcinoma
Negative Staining
Mutation
Urinary Bladder Neoplasms
Staining and Labeling
Chromosome Deletion
Cystectomy
beta Catenin
Aneuploidy
Cadherins
Adjuvant Chemotherapy
Fluorescence In Situ Hybridization
Neoplasms
Neoplasm Metastasis
Survival

ASJC Scopus subject areas

  • Urology

Cite this

Keck, B., Stoehr, R., Wach, S., Rogler, A., Hofstaedter, F., Lehmann, J., ... Hartmann, A. (2010). The plasmacytoid carcinoma of the bladder - rare variant of aggressive urothelial carcinoma. International Braz J Urol, 36(6), 770. https://doi.org/10.1590/S1677-55382010000600023

The plasmacytoid carcinoma of the bladder - rare variant of aggressive urothelial carcinoma. / Keck, B.; Stoehr, R.; Wach, S.; Rogler, A.; Hofstaedter, F.; Lehmann, J.; Montironi, R.; Sibonye, M.; Fritsche, H. M.; Lopez-Beltran, A.; Epstein, Jonathan Ira; Wullich, B.; Hartmann, A.

In: International Braz J Urol, Vol. 36, No. 6, 12.2010, p. 770.

Research output: Contribution to journalArticle

Keck, B, Stoehr, R, Wach, S, Rogler, A, Hofstaedter, F, Lehmann, J, Montironi, R, Sibonye, M, Fritsche, HM, Lopez-Beltran, A, Epstein, JI, Wullich, B & Hartmann, A 2010, 'The plasmacytoid carcinoma of the bladder - rare variant of aggressive urothelial carcinoma', International Braz J Urol, vol. 36, no. 6, pp. 770. https://doi.org/10.1590/S1677-55382010000600023
Keck, B. ; Stoehr, R. ; Wach, S. ; Rogler, A. ; Hofstaedter, F. ; Lehmann, J. ; Montironi, R. ; Sibonye, M. ; Fritsche, H. M. ; Lopez-Beltran, A. ; Epstein, Jonathan Ira ; Wullich, B. ; Hartmann, A. / The plasmacytoid carcinoma of the bladder - rare variant of aggressive urothelial carcinoma. In: International Braz J Urol. 2010 ; Vol. 36, No. 6. pp. 770.
@article{f529630c6e024900acd923ea20cd54cf,
title = "The plasmacytoid carcinoma of the bladder - rare variant of aggressive urothelial carcinoma",
abstract = "The WHO classification of 2004 defines new histological and molecular variants of urothelial carcinoma. However there are limited data available on the clinico-pathological characteristics or prognosis of these variants. We present histopathological, molecular and clinical data of 32 plasmacytoid carcinomas of the bladder (PUC) showing that PUC is a high-grade tumor with molecular features of aggressive urothelial carcinoma, usually diagnosed in advanced pathological stage (64{\%} pT3, 23{\%} pT4) showing metastases in 60 {\%} of the patients. Average survival of our cohort of PUC treated with radical cystectomy and adjuvant chemotherapy was lower than what is typically seen for comparable conventional urothelial carcinomas. 87{\%} of the PUCs showed a negative or strongly reduced membranous staining of E-cadherin. Beta-catenin staining was negative in 22.5{\%} and 16.7{\%} of the remaining tumors showed nuclear accumulation. Aberrant CK20 expression (negative or > 10{\%} of cells stained) and negative CK7 staining was found in 100{\%} and 22.6{\%}, respectively. 97{\%} revealed positive staining for PAN-CK. CD138 was positive in 78 {\%}, whereas MUM-1 expression was negative in all cases. Multi-target fluorescence in situ hybridization showed all PUCs to be highly aneuploid and polysomic. Deletions on chromosome 9p21 seem to play an important role in this variant. FGFR3 and PIK3CA mutation analyses yielded no mutations in any of the PUCs analyzed. TP53 mutation analysis showed mutations in 29{\%}. In summary, PUC is a aggressive variant of bladder cancer with molecular features of advanced bladder cancer and evidence of WNT pathway activation in some of the cases.",
author = "B. Keck and R. Stoehr and S. Wach and A. Rogler and F. Hofstaedter and J. Lehmann and R. Montironi and M. Sibonye and Fritsche, {H. M.} and A. Lopez-Beltran and Epstein, {Jonathan Ira} and B. Wullich and A. Hartmann",
year = "2010",
month = "12",
doi = "10.1590/S1677-55382010000600023",
language = "English (US)",
volume = "36",
pages = "770",
journal = "International braz j urol : official journal of the Brazilian Society of Urology",
issn = "1677-5538",
publisher = "Brazilian Society of Urology",
number = "6",

}

TY - JOUR

T1 - The plasmacytoid carcinoma of the bladder - rare variant of aggressive urothelial carcinoma

AU - Keck, B.

AU - Stoehr, R.

AU - Wach, S.

AU - Rogler, A.

AU - Hofstaedter, F.

AU - Lehmann, J.

AU - Montironi, R.

AU - Sibonye, M.

AU - Fritsche, H. M.

AU - Lopez-Beltran, A.

AU - Epstein, Jonathan Ira

AU - Wullich, B.

AU - Hartmann, A.

PY - 2010/12

Y1 - 2010/12

N2 - The WHO classification of 2004 defines new histological and molecular variants of urothelial carcinoma. However there are limited data available on the clinico-pathological characteristics or prognosis of these variants. We present histopathological, molecular and clinical data of 32 plasmacytoid carcinomas of the bladder (PUC) showing that PUC is a high-grade tumor with molecular features of aggressive urothelial carcinoma, usually diagnosed in advanced pathological stage (64% pT3, 23% pT4) showing metastases in 60 % of the patients. Average survival of our cohort of PUC treated with radical cystectomy and adjuvant chemotherapy was lower than what is typically seen for comparable conventional urothelial carcinomas. 87% of the PUCs showed a negative or strongly reduced membranous staining of E-cadherin. Beta-catenin staining was negative in 22.5% and 16.7% of the remaining tumors showed nuclear accumulation. Aberrant CK20 expression (negative or > 10% of cells stained) and negative CK7 staining was found in 100% and 22.6%, respectively. 97% revealed positive staining for PAN-CK. CD138 was positive in 78 %, whereas MUM-1 expression was negative in all cases. Multi-target fluorescence in situ hybridization showed all PUCs to be highly aneuploid and polysomic. Deletions on chromosome 9p21 seem to play an important role in this variant. FGFR3 and PIK3CA mutation analyses yielded no mutations in any of the PUCs analyzed. TP53 mutation analysis showed mutations in 29%. In summary, PUC is a aggressive variant of bladder cancer with molecular features of advanced bladder cancer and evidence of WNT pathway activation in some of the cases.

AB - The WHO classification of 2004 defines new histological and molecular variants of urothelial carcinoma. However there are limited data available on the clinico-pathological characteristics or prognosis of these variants. We present histopathological, molecular and clinical data of 32 plasmacytoid carcinomas of the bladder (PUC) showing that PUC is a high-grade tumor with molecular features of aggressive urothelial carcinoma, usually diagnosed in advanced pathological stage (64% pT3, 23% pT4) showing metastases in 60 % of the patients. Average survival of our cohort of PUC treated with radical cystectomy and adjuvant chemotherapy was lower than what is typically seen for comparable conventional urothelial carcinomas. 87% of the PUCs showed a negative or strongly reduced membranous staining of E-cadherin. Beta-catenin staining was negative in 22.5% and 16.7% of the remaining tumors showed nuclear accumulation. Aberrant CK20 expression (negative or > 10% of cells stained) and negative CK7 staining was found in 100% and 22.6%, respectively. 97% revealed positive staining for PAN-CK. CD138 was positive in 78 %, whereas MUM-1 expression was negative in all cases. Multi-target fluorescence in situ hybridization showed all PUCs to be highly aneuploid and polysomic. Deletions on chromosome 9p21 seem to play an important role in this variant. FGFR3 and PIK3CA mutation analyses yielded no mutations in any of the PUCs analyzed. TP53 mutation analysis showed mutations in 29%. In summary, PUC is a aggressive variant of bladder cancer with molecular features of advanced bladder cancer and evidence of WNT pathway activation in some of the cases.

UR - http://www.scopus.com/inward/record.url?scp=79251486326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251486326&partnerID=8YFLogxK

U2 - 10.1590/S1677-55382010000600023

DO - 10.1590/S1677-55382010000600023

M3 - Article

AN - SCOPUS:79251486326

VL - 36

SP - 770

JO - International braz j urol : official journal of the Brazilian Society of Urology

JF - International braz j urol : official journal of the Brazilian Society of Urology

SN - 1677-5538

IS - 6

ER -